What's Happening?
Arrowhead Pharmaceuticals has announced that its subsidiary, Visirna Therapeutics, has sold the rights to its hypertriglyceridemia candidate, plozasiran, to Sanofi for development and commercialization in Greater China. Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestones. Plozasiran is an investigational RNA interference therapeutic designed to reduce production of apolipoprotein C-III, a key regulator of triglyceride metabolism. Visirna has completed a Phase 3 clinical trial of plozasiran in Chinese patients, meeting primary and secondary efficacy endpoints, and has submitted a New Drug Application to China's National Medical Products Administration.
AD
Why It's Important?
This transaction is significant as it represents a strategic partnership between Arrowhead and Sanofi, leveraging Sanofi's strong presence in China to advance plozasiran's development. The deal highlights the potential of RNA interference therapeutics in addressing unmet medical needs, particularly in the cardiometabolic field. For Arrowhead, the agreement provides financial benefits and potential royalties, supporting its broader pipeline of investigational candidates. For Sanofi, acquiring plozasiran aligns with its focus on expanding its portfolio in China, addressing serious illnesses caused by elevated triglycerides.
What's Next?
Following the agreement, Sanofi will focus on advancing plozasiran through the regulatory process in China, aiming to bring the therapeutic to market. Visirna will receive milestone payments upon approval of plozasiran across various indications. Arrowhead will continue to develop its RNAi-based therapeutics, potentially exploring further partnerships to expand its global reach. The success of plozasiran in China could pave the way for similar agreements in other regions, enhancing the availability of innovative treatments for hypertriglyceridemia.
Beyond the Headlines
The sale of plozasiran rights to Sanofi underscores the growing importance of RNA interference technology in drug development. This approach offers a novel mechanism for gene silencing, which could lead to breakthroughs in treating various genetic disorders. The collaboration between Arrowhead and Sanofi may also influence other pharmaceutical companies to explore RNAi therapeutics, potentially accelerating advancements in personalized medicine and targeted therapies.
